4.97

2.74% -0.14

Pre-market: 4.91 -0.06 -1.21%

Passage Bio Inc (PASG)

Overview News Price History Option Chain Financials Discussions Forecast

Passage Bio Inc stock is traded at $4.97, with a volume of 25,225. It is down -2.74% in the last 24 hours and down -36.69% over the past month. Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.

Previous Close:

$5.11

Open:

$5.06

24h Volume:

25,225

Relative Volume:

0.37

Market Cap:

$15.94M

Revenue:

Net Income/Loss:

$-45.52M

P/E Ratio:

-0.511

EPS:

-9.7265

Net Cash Flow:

$-31.51M

1W Performance:

-14.90%

1M Performance:

-36.69%

6M Performance:

-35.29%

1Y Performance:

+1,383%

1-Day Range:

$4.828

$5.155

1-Week Range:

$4.828

$5.98

52-Week Range:

$0.257

$20.00

Passage Bio Inc Stock (PASG) Company Profile

Name

Passage Bio Inc

Sector

Healthcare (1112)

Industry

Biotechnology (622)

Phone

(267) 866-0312

Address

ONE COMMERCE SQUARE, PHILADELPHIA, PA

Employee

Twitter

@passage_bio

Next Earnings Date

2026-05-12

Latest SEC Filings

PASG's Discussions on Twitter

Compare PASG vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PASG Passage Bio Inc	4.97	15.94M	0	-45.52M	-31.51M	-9.7265
VRTX Vertex Pharmaceuticals Inc	423.92	107.83B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	701.42	73.54B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	783.50	48.72B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	296.11	39.51B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	293.86	32.66B	5.36B	287.73M	924.18M	2.5229

Passage Bio Inc Stock (PASG) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-21-26	Downgrade	Chardan Capital Markets	Buy → Neutral
Apr-21-26	Downgrade	TD Cowen	Buy → Hold
Apr-21-26	Downgrade	Wedbush	Outperform → Neutral
Mar-31-26	Initiated	Oppenheimer	Outperform
Feb-10-26	Resumed	Chardan Capital Markets	Buy
Nov-29-24	Resumed	Wedbush	Outperform
Sep-03-24	Initiated	Rodman & Renshaw	Buy
Mar-08-22	Downgrade	JP Morgan	Overweight → Neutral
Jan-19-22	Downgrade	Goldman	Buy → Neutral
Jul-01-21	Initiated	Raymond James	Outperform
Jun-15-21	Initiated	BTIG Research	Buy
Mar-04-21	Upgrade	Goldman	Neutral → Buy
Feb-04-21	Initiated	Guggenheim	Buy
Jan-25-21	Initiated	Wedbush	Outperform
Jan-04-21	Upgrade	JP Morgan	Neutral → Overweight
Dec-11-20	Initiated	Citigroup	Neutral
Aug-14-20	Downgrade	JP Morgan	Overweight → Neutral
Jun-25-20	Downgrade	Goldman	Buy → Neutral
Mar-25-20	Initiated	Chardan Capital Markets	Buy
Mar-24-20	Initiated	Cowen	Outperform
Mar-24-20	Initiated	Goldman	Buy
Mar-24-20	Initiated	JP Morgan	Overweight

View All

Passage Bio Inc Stock (PASG) Latest News

Apr 28, 2026

Passage Bio Announces Major Workforce Reduction and Restructuring - TipRanks

Apr 28, 2026

Passage Bio (NASDAQ: PASG) slashes workforce by 75% in 2026 restructuring - Stock Titan

Apr 28, 2026

Apr 27, 2026

Passage Bio Reports Trial Data, Reviews Strategic Options - MyChesCo

Apr 27, 2026

Apr 26, 2026

Chardan Capital Maintains Passage Bio (PASG) Buy Recommendation - MSN

Apr 26, 2026

Passage Bio Inc (PASG)

Passage Bio Inc Stock (PASG) Company Profile

Compare PASG vs VRTX, REGN, ARGX, ALNY, ONC

Passage Bio Inc Stock (PASG) Upgrades & Downgrades

Passage Bio Inc Stock (PASG) Latest News

Passage Bio Announces Major Workforce Reduction and Restructuring - TipRanks

Passage Bio (NASDAQ: PASG) slashes workforce by 75% in 2026 restructuring - Stock Titan

Passage Bio Reports Trial Data, Reviews Strategic Options - MyChesCo

Chardan Capital Maintains Passage Bio (PASG) Buy Recommendation - MSN

Canaccord Genuity Remains a Buy on Passage Bio (PASG) - The Globe and Mail

PASG Maintains Rating by Oppenheimer -- Price Target Lowered to $15 - GuruFocus

PASG Downgraded by Chardan Capital -- Price Target Lowered to $7 - GuruFocus

Passage Bio (PASG) Downgraded by Wedbush Analyst - GuruFocus

PASG Downgraded by TD Cowen -- Rating Changed to Hold - GuruFocus

Passage Bio Faces Tougher FDA Road After Trial Shift, Wedbush Says - marketscreener.com

PASG Downgraded by Wedbush -- Price Target Lowered to $8.00 - GuruFocus

Passage Bio Seen as Undervalued Despite FDA Setback, Oppenheimer Says - marketscreener.com

Passage Bio downgraded to Neutral from Buy at Chardan - TipRanks

This Mohawk Industries Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Tuesday - Benzinga

Passage Bio stock rating cut to Hold by TD Cowen on FDA trial news - Investing.com South Africa

Oppenheimer Adjusts Price Target on Passage Bio to $15 From $30, Maintains Outperform Rating - marketscreener.com

Wedbush Downgrades Passage Bio to Neutral From Outperform, Cuts Price Target to $8 From $32 - marketscreener.com

Oppenheimer cuts Passage Bio stock price target on regulatory setback - Investing.com

Oppenheimer cuts Passage Bio stock price target on regulatory setback By Investing.com - Investing.com Australia

Passage Bio Announces PBFT02 Data and Strategic Review - The Globe and Mail

Chardan Downgrades Passage Bio to Neutral From Buy, Cuts Price Target to $7 From $21 - marketscreener.com

Chardan downgrades Passage Bio stock rating on strategic review By Investing.com - Investing.com South Africa

Chardan downgrades Passage Bio stock rating on strategic review - Investing.com

Passage Bio to Present at H.C. Wainwright Global Investment Conference - MSN

Wedbush Maintains Passage Bio(PASG.US) With Buy Rating, Maintains Target Price $32 - Moomoo

New Developments for Passage Bio (PASG) in Frontotemporal Dement - GuruFocus

Is Passage Bio (PASG) stock safe today (Underperforming) 2026-04-20Viral Momentum Stocks - Xã Thanh Hà

Lucid downgrades Passage Bio stock rating on funding concerns By Investing.com - Investing.com South Africa

Lucid downgrades Passage Bio stock rating on funding concerns - Investing.com

Passage Bio Starts Strategic Review After FDA Doesn't Support Single-Arm Trial - Moomoo

Passage Bio Reports Positive Interim Data for PBFT02 in FTD-GRN, Initiates Strategic Review After FDA Guidance 1 - Minichart

Passage Bio reports biomarker improvements in FTD trial - Investing.com

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Passage Bio reports biomarker improvements in FTD trial By Investing.com - Investing.com Canada

Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates - The Manila Times

Gene therapy company Passage Bio, Inc. recently disclosed two major decisions: the official appointment of Wedbush Pacgrow as its financial advisor, and the commencement of a comprehensive evaluation of strategic alternatives. - Bitget

Strategic review at Passage Bio (NASDAQ: PASG) after FDA trial guidance - Stock Titan

Leading Companies Fueling Innovation and Growth in the GM1 Gangliosidosis Market - openPR.com

Short Squeeze: What is the earnings history of Passage Bio IncTrade Entry Report & Consistent Profit Focused Trading Strategies - baoquankhu1.vn

12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga

PMN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Trends in Growth, Segment Analysis, and Competitive Strategies Influencing the Adeno-Associated Viral Vectors Market - openPR.com

PASG PE Ratio & Valuation, Is PASG Overvalued - Intellectia AI

Passage Bio Inc Stock (PASG) Financials Data

Revenue

Net Income

Cash Flow

EPS

Similar to PASG